

REMARKS/ARGUMENTS

Reconsideration of this application is requested.

In Section 102 of the Office Action, item 3, the Examiner says that Weinstock et al. disclose 6-methoxy-7-chloro-2-aminotetraline hydrochloride and 6-chloro-7-methoxy-2-aminotetraline hydrochloride.

In claim 8, formulae (I) (II) have substituents in position 5, 6 and 7, named as R_2 , R and R_1 , respectively. In the amendment filed on March 29, 2004, claim 8 contains several disclaimers, two of which are directly relevant to the Examiner's argument.

Disclaimers (k) and (l) exclude the compounds of formulae (I) and (II) in which $R_2 = H$, $R = \text{methoxy}$ and $R_1 = \text{chloro}$, i.e., 6-methoxy-7-chloro-2-aminotetraline.


Disclaimer (l) excludes the compounds of formulae (I) and (II) in which $R_2 = H$, $R = \text{chloro}$ and $R_1 = \text{methoxy}$, i.e., and 6-chloro-7-methoxy-2-aminotetraline. Accordingly, applicant's claims 8, 9 and 11 do not include Weinstock's compounds.

For the above reasons, it is respectfully submitted that the claims of this application define inventive subject matter. Entry of this Amendment and allowance are solicited. Should the examiner have any questions, please contact the undersigned by telephone.

FANTO et al.
Appl. No. 09/533,381
November 23, 2004

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 
Arthur R. Crawford
Reg. No. 25,327

ARC:maw
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100